As of 2025-09-18, the Intrinsic Value of Kalvista Pharmaceuticals Inc (KALV) is -15.53 USD. This KALV valuation is based on the model Peter Lynch Fair Value. With the current market price of 13.38 USD, the upside of Kalvista Pharmaceuticals Inc is -216.09%.
Based on its market price of 13.38 USD and our intrinsic valuation, Kalvista Pharmaceuticals Inc (KALV) is overvalued by 216.09%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.53 - -15.53 | -15.53 | -216.09% |
| P/E | (39.70) - (42.06) | (40.93) | -405.9% |
| DDM - Stable | (30.23) - (118.27) | (74.25) | -655.0% |
| DDM - Multi | (7.56) - (23.53) | (11.51) | -186.0% |
| Market Cap (mil) | 673.55 |
| Beta | 0.98 |
| Outstanding shares (mil) | 50.34 |
| Enterprise Value (mil) | 647.82 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.78% |
| Cost of Debt | 5.00% |
| WACC | 8.11% |